PsyBio Therapeutics Corp.
PsyBio Therapeutics Corp.
Your view on PSYBF
Overview
What the company does, where it operates, and who runs it.
About PsyBio Therapeutics Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Evan Mike Levine
- Headquarters
- 4400 West Sample Road, Coconut Creek, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Evan Mike Levine
- Headquarters
- 4400 West Sample Road, Coconut Creek, FL, US
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for PsyBio Therapeutics Corp., and the rating behind it. PSYBF last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for PsyBio Therapeutics Corp.. Starting points for PsyBio Therapeutics Corp.: EPS -$0.04, beta 4.67 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for PsyBio Therapeutics Corp.. PsyBio Therapeutics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for PsyBio Therapeutics Corp.. Trailing twelve-month EPS for PsyBio Therapeutics Corp. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for PsyBio Therapeutics Corp.. PsyBio Therapeutics Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
PsyBio Therapeutics Corp. valued side by side against its closest peers. PsyBio Therapeutics Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold PsyBio Therapeutics Corp., and how their positions are changing. At a $1,275 market value, institutional positions materially move PsyBio Therapeutics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by PsyBio Therapeutics Corp. executives and directors. Shares of PsyBio Therapeutics Corp. have traded between $0.0000 and $0.0050 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming PsyBio Therapeutics Corp.. PsyBio Therapeutics Corp. is a $1,275 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming PsyBio Therapeutics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for PsyBio Therapeutics Corp.. Coverage tracks PsyBio Therapeutics Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.